rolipram has been researched along with Prostatic Hyperplasia in 1 studies
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "New therapeutic targets in benign prostatic hyperplasia (BPH) mainly concern phosphodiesterase type 5 (PDE-5) inhibitors." | 1.34 | [Recent progress in basic research concerning the management of benign prostatic hyperplasia]. ( Cornu, JN; Rouprêt, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cornu, JN | 1 |
| Rouprêt, M | 1 |
1 other study available for rolipram and Prostatic Hyperplasia
| Article | Year |
|---|---|
[Recent progress in basic research concerning the management of benign prostatic hyperplasia].
Topics: Colforsin; Humans; Male; Muscle Contraction; Muscle, Skeletal; Phenylephrine; Piperazines; Prostatic | 2007 |